Skip to main content
Premium Trial:

Request an Annual Quote

Codexis, Casdin Capital Invest $10M in Molecular Assemblies

NEW YORK – Codexis and Casdin Capital said on Thursday that they have invested a combined $10 million in enzymatic DNA synthesis company Molecular Assemblies.

Codexis invested $7 million, a spokesperson said in an email, while Casdin separately contributed $3 million. Codexis said the deal makes it the second-largest shareholder in Molecular Assemblies.

The investments are enabled through Codexis and Casdin's SynBio Innovation Accelerator, which the firms launched in December 2020, and are part of Molecular Assemblies' ongoing Series B financing round.

"Molecular Assemblies is a pioneer in the field of enzymatic DNA synthesis and this additional investment in the company underscores our belief in our groundbreaking collaboration to enable the cost-effective production of synthetic DNA," Codexis CEO John Nicols said in a statement. "Substantial enzyme improvements have been needed to unlock the potential of enzymatic DNA synthesis, and I am proud to share that these are on track to be achieved shortly."

San Diego-based Molecular Assemblies extended its Series A financing by $11.8 million in April after initially announcing it had raised $12.2 million.

Last year, Molecular Assemblies partnered with Codexis to improve its DNA synthesis method with Codexis' CodeEvolver protein engineering platform.

The Scan

UK Moves to Allow Sale of Gene-Edited Food

The UK is moving ahead to allow the sale of gene-edited food in England, Scotland, and Wales, according to New Scientist.

Questions for the Field

Stat News writes that the alleged Buffalo shooter's citation of genetics research raises questions about what the field can do.

Cell Studies on Tumor Evolution in Mouse Model of Lung Cancer, Stereo-seq, Bacteriophage Responses

In Cell this week: tumor evolution tracked in mouse model of lung cancer, organogenesis mapped using Stereo-seq, and more.

Taking Stock of the Stockpile

The US and European countries are evaluating their smallpox vaccine stockpiles as the number of monkeypox cases increases, the Washington Post reports.